Search Results

You are looking at 21 - 30 of 167 items for :

  • "BRAF mutation" x
  • Refine by Access: All x
Clear All
Full access

Karina Mayra Aliaga, Fradis Gil-Olivares, Laura Pérez, Gisely Hijar, Edward López, Cindy Alcarraz, Mariana Serrano, Claudio Flores, Alonso Díaz, Jose Gutierrez, and Alfredo Aguilar

RAS and BRAF mutational status to patients with metastatic CRC and percentage of patients who received recommended therapy according to the RAS and/or BRAF mutational status. Methods: A descriptive analysis was performed. Indicators were compared

Full access

Krishna Desai, Kristal Pereira, Akhil Jain, Sabah Iqbal, and Rajesh Thirumaran

, fluorouracil, & oxaliplatin) was started, but a new metastatic lesion in the liver was found. In the interim, NGS was positive for IDH-1 & BRAF mutation. Since he was progressing, target therapy with Ivosidenib was added for IDH-1, as per NGS. At 2 year follow

Full access

.2011 (Rectal). Based upon recent presentations, the previous footnote related to BRAF mutations was removed and the following footnotes were added to the metastatic section of the NCCN Guidelines for Colon and Rectal Cancers: Footnote in the first

Full access

Wells A. Messersmith

the NTRK inhibitor larotrectinib, and some additional language regarding Lynch syndrome and testing, both in terms of expression of the markers and the fact that a BRAF mutation doesn’t rule out Lynch syndrome,” he said at the NCCN 2019 Annual

Full access

Protocol Chair: Manisha Shah, MD Institutional Principal Investigators: Manisha Shah, MD, and Filip Janku, MD, PhD Condition: Adult malignant tumors with BRAF mutation Institutions: The Ohio State University Comprehensive Cancer Center - James

Full access

safety of the orally administered MEK inhibitor trametinib in subjects with melanoma harboring mutations in BRAF at locations other than codon 600 (atypical BRAF mutations; BRAF non-V600MUT) or BRAF fusions. More than 5% of melanomas harbor these

Full access

and safety of the orally administered MEK inhibitor trametinib (GSK1120212) in subjects with melanoma harboring mutations in BRAF at locations other than codon 600 (atypical BRAF mutations; BRAF non-V600 MUT ) or BRAF fusions. More than 5% of

Full access

Trametinib (MEKi) in Patients With BRAF Mutation or BRAF Gene Fusion Defect in Thyroid Carcinoma Protocol Chair: Manisha Shah, MD Institutional Principal Investigators: Manisha Shah, MD; Naifa L. Busaidy, MD; Lori Wirth, MD; Jonas DeSouza, MD; and

Full access

Mackenzie Taychert, Ankita Aggarwal, David Tabagari, Urja Nagadia, Sai Gajagowni, Venkata Vosuri, and Kushal Naha

Introduction: BRAF mutations in advanced stage colorectal cancers are observed in 8-12% of patients and BRAF V600E is the most frequent alteration. This mutation confers poor prognosis and treatment outcomes with routine systemic chemotherapy

Full access

Henry G. Kaplan

tumors Discuss the potential benefits of vemurafenib in the presence of a BRAF mutation Malignant peripheral nerve sheath tumors (MPNSTs) are uncommon cancers that can demonstrate extremely aggressive behavior. Primary treatment involves surgical